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ments. The Transactional Model of Stress and Coping was used
as the theoretical framework for the study and self-report data
on diabetes-related stress, views of diabetes, coping and HRQoL
were obtained. The Short-Form 8 (SF-8) was used to measure
HRQoL by determining the overall mental component (MCS)
and physical component scores (PCS). Path analysis via multiple
regression analysis was used to evaluate the relationships pro-
posed in the study model. Age, gender, race, education, marital
status, insurance, smoking, insulin use, body mass index, Charl-
son comorbidity score, history of depression, duration of dia-
betes and HbA1C values were incorporated into the model as
control variables. RESULTS: A total of 217 surveys were col-
lected with a usable response rate of 93%. The mean age of the
overall sample was 57.3 years (SD = 11.9), 62.2% were female
and 61% were Hispanic. High diabetes-related stress was asso-
ciated with a negative view of diabetes (b = 0.60, p < 0.001). A
negative view of diabetes was associated with decreased use of
problem-focused coping (b = -0.23, p < 0.05), increased use of
avoidance (b = 0.32, p < 0.001), passive resignation (b = 0.64,
p < 0.001) and poor diabetes integration (b = 0.57, p < 0.001).
Passive resignation coping was in turn associated with a lower
PCS (b = -0.20, p < 0.01). Lower MCS was associated with
passive resignation (b = -0.21, p < 0.01) and poor diabetes inte-
gration (b = -0.20, p < 0.01). CONCLUSIONS: Passively resign-
ing oneself to diabetes was found to be associated with a lower
PCS and MCS. Poor integration of diabetes into one’s life was
also associated with lower MCS. Stress management and coping
skills training may improve HRQoL in patients with T2DM.
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USE OF MEDICATION COVERAGE METHODOLOGY IN
MEASUREMENT OF PATIENT COMPLIANCE WITH
PHARMACOTHERAPY
Stern L, Doyle J, Siegartel LR, Katz LM, Dolgitser M
Analytica International, New York, NY, USA
OBJECTIVES: The measurement of patient compliance to med-
ications in a large database analysis presents inherent challenges,
such as concomitant prescriptions, switches and add-ons. The
Medication Coverage (MC) methodology is an application of the
Medication Possession Ratio (MPR) that allows for considera-
tion of multiple prescriptions simultaneously or serially. The 
beneﬁts of this approach to outcomes research are explored.
METHODS: In 3864 patients with primary open-angle glau-
coma (POAG), a prescription for a glaucoma medication, and a
minimum 2 years of continuous enrollment post-index date (date
of ﬁrst glaucoma therapy) were identiﬁed within the PharMet-
rics database. MC was calculated as the proportion of days a
patient was in possession of any glaucoma medication during the
ﬁrst year of follow-up. Medication possession on each day was
considered as a binomial variable (presence or absence of med-
ication), independent of whether patients were on one or multi-
ple medications. We designated the 75th percentile of the MC
score to stratify patients as “more” versus “less” compliant.
“More Compliant” was then tested as a predictor in multivari-
ate logistic models, while controlling for key covariates, pre-
dicting ocular surgery in year two of follow-up. RESULTS: The
MC methodology applied in this sample data showed that mean
MC was 0.47 and 75th percentile MC was 0.67. Coverage was
normally distributed. Logistic regression models showed that as
severity of POAG patients increases, compliance with pharma-
cotherapies is increasingly associated with a reduced risk of glau-
coma surgery. CONCLUSIONS: MC can be used to examine
patient compliance with medication in large retrospective data-
base analyses. This technique allows for analysis of patient com-
pliance to medication while considering concomitant medica-
tions and various treatment patterns.
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COST-EFFECTIVENESS OF A GLAUCOMA-SCREENING
PROGRAM: A MODEL EVALUATING THE RELATIVE CLINICAL
AND ECONOMIC IMPACT IN COMMERCIAL VS. SENIOR
MEMBER POPULATIONS
Goldberg LD1,Walt JG2
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OBJECTIVES: Positive return on investment (ROI) for disease
management (DM) programs has generally been limited to those
managing congestive heart failure or multiple disease conditions.
It is the objective of this model to evaluate the ROI of a glau-
coma-screening DM program in Commercial vs. Senior member
populations. METHODS: An interactive Excel-based 14-year
economic model previously developed to assess the payer costs
associated with screening and early treatment of glaucoma
patients vs. non-screening of asymptomatic progressive disease
was extended to dynamically model the drug treatment compo-
nent. Treatment costs and disease progression rates were taken
from the published literature. Drug costs were based on average
wholesale price cost with consideration of contractual discounts
and patient co-payment. The primary economic endpoint was
the ratio of reduced annual treatment costs compared to annual
program costs. Multi-factor sensitivity analyses were conducted.
RESULTS: In a Commercial population, total annual costs to
“screen and treat” vs. a strategy of no screening was estimated
to be $0.62 PMPM vs. $0.80 PMPM respectively (a difference
of $0.12 PMPM in favor of screening). In the Senior population,
these costs were estimated to be $6.66 PMPM vs. $7.94 PMPM
respectively (a difference of $1.28 PMPM in favor of screening).
With estimated program costs of $0.009 PMPM and $0.167
PMPM in the Commercial vs. Senior populations respectively,
the calculated potential ROI was estimated to be 2.6 and 1.7
respectively for these programs. CONCLUSION: The early iden-
tiﬁcation and treatment of glaucoma in accordance with estab-
lished evidence-based clinical practice guidelines represents a
more cost-effective strategy as compared to non-screening of at
risk populations. Total annual costs for a glaucoma-screening
disease management program are estimated to demonstrate a
positive ROI in both Commercial and Senior populations. These
ﬁndings may help promote the interest of payers in implement-
ing pertinent quality improvement and HEDIS-related efforts.
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AN AUDIT OF 106 ECONOMIC ANALYSES CONTAINED IN
AMCP DOSSIER SUBMISSIONS 2002–2005 
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OBJECTIVES: To investigate the quality of economic analyses
submitted by pharmaceutical manufacturers to health plans
under the Academy of Managed Care Pharmacy (AMCP) Format
for formulary submissions. To compare quality of economic
analyses between high-cost and other products, and between
“me-too” and other drugs. METHODS: We reviewed all eco-
nomic analyses included in AMCP-Format dossiers submitted by
pharmaceutical companies to Premera Blue Cross (Mountlake
Terrace, WA, enrollment 1.5 million) between January 2002 and
September 2005. Economic analyses were deﬁned as research
studies or mathematical models that combined clinical and cost
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data to estimate the value of a drug for an indication. We
assessed analyses’ compliance with several criteria recommended
by the Panel on Cost-Effectiveness in Health and Medicine.
RESULTS: Of 115 dossiers submitted, 55% included economic
analyses. We found 106 analyses supporting economic claims for
drugs on speciﬁc indications. Of these, 89% adopted a payer per-
spective, 48% were cost minimization analyses, 58% had time
horizons < 2 years. 14% applied discounting; 20% stated all
assumptions clearly; 37% compared relevant alternatives; 21%
reported resource quantities separately, 13% productivity losses,
and 26% incremental results; 42% performed some form of sen-
sitivity analysis; 18% mentioned caveats to conclusions. Analy-
ses of high-cost products were more likely to be cost effectiveness
or cost consequence analyses (OR = 12.5, p = 0.004) and to
compare relevant alternatives (OR = 6.4, p = 0.008). Analyses of
me-too drugs were less likely to state all assumptions clearly 
(OR = 0.23, p = 0.016), compare relevant alternatives (OR =
0.09, p = 0.0001), report sensitivity analyses (OR = 0.19, 
p = 0.006) or incremental results (OR = 0.28, p = 0.03). No 
other signiﬁcant differences found. CONCLUSIONS: Most 
AMCP-Format dossier submissions included economic analyses,
but these had low levels of compliance with accepted recom-
mendations. Analyses of me-too drugs appeared particularly
prone to bias.
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ANTIPSYCHOTIC USE IN AMBULATORY CARE FROM 1996 
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OBJECTIVES: Conventional typical-antipsychotics are less tol-
erated than newer atypical-antipsychotics. Concerns about using
antipsychotic-combinations also exist. However, national studies
of antipsychotic use at United States (US) ambulatory visits are
limited. The study objectives were to determine national esti-
mates and associated factors of antipsychotic (typical, atypical,
and combination) use. METHODS: Retrospective analyses were
conducted of the combined 8-year data (1996–2003) of ofﬁce-
based National Ambulatory Medical Care Survey (NAMCS) and
outpatient National Hospital Ambulatory Medical Care Survey
(NHAMCS). Mental-health disorder visits with ICD-9-CM 
diagnostic-codes (290–319, 331.0x) were classiﬁed into three
mutually exclusive visit-groups: typical, atypical or combined-
antipsychotic. Sample estimates were weighted and projected to
the population with 95% conﬁdence intervals. Multivariable
logistic regression was used to determine signiﬁcant factors asso-
ciated with typical- versus atypical-antipsychotic mention at
visits. RESULTS: About 47.7million visits or 0.83%
(95%CI:0.73–0.93) of all adult visits had a mental-health disor-
der and an antipsychotic mention: atypical (30 million visits),
typical (15.3 million visits), and combination (2.4 million visits).
Major antipsychotics across visit-groups were: typical (haloperi-
dol, thioridazine, ﬂuphenazine); atypical (risperidone, olanzap-
ine, quiteapine); and combination (haloperidol, risperidone,
olanzapine). Compared with typical-, the likelihood of atypical-
antipsychotic visits increased over time. More typical- and 
combination- versus atypical-antipsychotic visits (30% and 
37% vs. 7%) included medications to treat extrapyramidal side
effects (EPS). In multivariable logistic-regression analysis, con-
trolling for gender, schizophrenia-diagnosis, and behavioral-
treatment; age greater than 40 versus 18–40 years (odds-ratio,
OR, 0.65, 95%CI:0.49–0.85) and nonprivate insurance 
reimbursement-sources signiﬁcantly decreased while comorbid
depression (OR, 1.9, 95%CI:1.23–2.85), and bipolar-disorder
(OR, 2.0, 95%CI:1.27–3.24), signiﬁcantly increased the likeli-
hood of atypical- relative to typical-antipsychotic mention at
visits (p < 0.05). CONCLUSIONS: Although combination-
antipsychotic visits were low, 37% of these visits included med-
ications to treat EPS. Atypical-antipsychotic use was more likely
at visits by younger patients, with comorbid diagnoses (depres-
sion, bipolar-disorder), and private insurance reimbursement-
source. This highlights important case-mix factors of




VALIDATION OF THE HYPERPIGMENTATION TREATMENT
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OBJECTIVES: To reﬁne and evaluate the validity and reliability
of the Hyperpigmentation Treatment Satisfaction Questionnaire
(HPTSQ). The HPTSQ was designed to measure medication
treatment satisfaction for subjects with hyperpigmentation,
either melasma (pregnancy mask) or solar lentigines (age spots).
METHODS: All analyses were conducted on data from a cross-
sectional sample of subjects who reported having hyperpigmen-
tation and completed the HPTSQ online. RESULTS: A total of
635 respondents (573 with solar lentigines and 62 with melasma)
completed the HPTSQ. Factor analysis, Item Response Theory
(IRT) and traditional psychometric analyses were used to select
the 26 items in ﬁve factors/ domains from an initial pool of 38
items. These ﬁve domains had the following properties: 1) Efﬁ-
cacy—7 items, á coefﬁcient 0.96; 2) Side Effects—5 items, á coef-
ﬁcient 0.95; 3) Physical Properties—5 items, á coefﬁcient 0.88;
4) Convenience—5 items, á coefﬁcient 0.87; and 5) Overall Sat-
isfaction—4 items, á coefﬁcient 0.93. Domains 1, 3, 4, and 5
showed strong test-retest reliability (intra-class correlations
0.77–0.87), while Domain 2 had an ICC of 0.44 (0.52 for sub-
jects reporting side effects at both baseline and follow-up). All
domains of the HPTSQ showed strong construct validity when
correlated with related domains on three comparable patient-
reported instruments. Based on level of treatment satisfaction,
all domains of the HPTSQ showed strong known-groups valid-
ity (p < 0.01), except Domain 2 (Side Effects). CONCLUSIONS:
The 26-item HPTSQ is a psychometrically sound and valid
measure of solar lentigines and melasma subjects’ treatment sat-
isfaction with medication. Responsiveness testing of the HPTSQ
should be conducted in a prospective clinical trial.
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QUESTIONNAIRE: RESULTS OF THE MATRIX STUDY
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OBJECTIVE: To determine the validity and sensitivity to change
of the Work Productivity Questionnaire (WPQ) in a large,
national sample of participants in the Multicenter Assessment of
Transdermal Therapy in Overactive Bladder with Oxybutynin
(MATRIX). METHODS: The WPQ is an 8-item subset of the
Work Limitations Questionnaire (WLQ) which measures the
